N.I. BEYLINA, E.A. ATSEL, A.O. POZDNYAK

 Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

 Contact details:

Beylina N.I. — PhD (medicine), Associate Professor of the Department of Therapy, Geriatrics and Family Medicine

Address: 36 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-905-023-66-45, e-mail: nataliabeylina@mail.ru

The article analyzes Russian and foreign literature on the use of dietary supplements by people of different ages. The frequent use of food additives both around the world and in Russia, the peculiarities of their production and promotion in the pharmaceutical market make the problem of their safe use urgent. In some cases, dietary supplements can cause liver damage. The issues of diagnosis and treatment of medicinal liver lesions are discussed.

Conclusion. Dietary supplements can and should be used to correct the daily diet nowadays. In clinical practice, a doctor faces the following tasks: identification of risk factors for medicinal liver damage due to the use of dietary supplements, diagnosis of their early manifestations and treatment of existing liver pathology.

Key words dietary supplements, liver diseases, risk factors, diagnostics, treatment.

(For citation: Beylina N.I., Atsel E.A. , Pozdnyak A.O. Dietary supplements and medicinal liver damage. Practical medicine. 2023. Vol. , № , P.)

REFERENCES

1. Illarionova E.A., Syrovatskiy I.P. Biologicheski aktivnye i pishchevye dobavki. Otsenka effektivnosti i bezopasnosti: uchebnoe posobie [Biologically active and nutritional supplements. Efficacy and safety assessment: training manual]. Irkutsk: IGMU, 2020. 56 p.
2. Federal’nyy zakon ot 2.01.2000 no. 29-FZ “O kachestve i bezopasnosti pishchevykh produktov” (Sobranie zakonodatel’stva RF, 2000, no. 2, st. 150; 2002, no. 1, st. 2; 2003, no. 2, st. 167; no. 27, st. 2700; 2004, no. 35, st. 3607; 2005, no. 19, st. 1752; no. 50, st. 5242; 2006, no. 1, st. 10; no. 14, st. 1458; 2007, no. 1, st. 29; 2008, no. 30, st. 3616; 2009, no. 1, st. 17, 21; 2011, no. 1, st. 6; no. 30, st. 4590, 4596; 2015, no. 1, st. 85; no. 29, st. 4339; 2018, no. 18, st. 2571; 2019, no. 52, st. 7765) [Federal Law of January 2, 2000 No. 29-FZ “On the quality and safety of food products” (Collected Legislation of the Russian Federation, 2000, No. 2, Art. 150; 2002, No. 1, Art. 2; 2003, No. 2, Art. 167; No. 27, Art. 2700; 2004, No. 35, Art. 3607; 2005, No. 19, Art. 1752; No. 50, Art. 5242; 2006, No. 1, Art. 10; No. 14, Art. 1458; 2007, No. 1, Art. 29; 2008, No. 30, Art. 3616; 2009, No. 1, Art. 17, 21; 2011, No. 1, Art. 6; No. 30, Art. 4590, 4596; 2015, No. 1, Art. 85; No. 29, Art. 4339; 2018, No. 18, Art. 2571; 2019, No. 52, Art. 7765)].
3. Belousova O.V., Belousov E.A., Ivashchenkova A.O. Dietary supplements as a promising direction for the development of the pharmaceutical market. Nauchnyy rezul’tat. Meditsina i farmatsiya, 2016, vol. 4, no. 4 (in Russ.).
4. Rene Makgregor. Sportivnoe pitanie: chto est’ do, vovremya i posle trenirovok [Sports nutrition: what to eat before, during and after training]. Moscow: Al’pina Pablisher, 2016. P. 16. 304 p.
5. Kalashnikova R.V., Lelyavina A.K. Tendentsii v ispol’zovanii biologicheski aktivnykh dobavok sredi studentov, zanimayushchikhsya funktsional’nymi trenirovkami [Trends in the use of dietary supplements among students engaged in functional training]. Sbornik statey XXI Vserossiyskoy nauchno-prakticheskoy konferentsii. Irkutsk: Izd-vo: Vostochno-Sibirskiy institut MVD RF, 2019. Pp. 301–303.
6. Elinav E., Pinsker G., Safadi R., Pappo O. et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J. Hepatol, 2007, vol. 47 (4), pp. 514–520.
7. Roytman M.M., Pörzgen P., Lee C.L., Huddleston L. et al. Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. Am. J. Gastroenterol, 2014, vol. 109 (8), pp. 1296–1298.
8. Björnsson E.S., Bergmann O.M., Björnsson H.K., Kvaran R.B. et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology, 2013, vol. 144 (7), pp. 1419–1425.
9. Olefir Yu.V., Medunitsyn N.V., Avdeeva Zh.I. et al. Modern biological / biotechnological drugs. Current development issues and prospects for use. BIO preparaty. Profilaktika, diagnostika, lechenie, 2016, vol. 16, no. 2, pp. 67–77 (in Russ.).
10. Burova E.D., Khod’ko S.V., Gushchina S.V. et al. Risk management to ensure the quality of preclinical studies of drugs. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya, 2017, vol. 7, no. 1, pp. 25–32 (in Russ.).
11. Formulyarnyy komitet RAMN. Doklad o sostoyanii lekarstvennogo obespecheniya naseleniya v Rossiyskoy Federatsii (2008 g.) [Formulary Committee of the Russian Academy of Medical Sciences. Report on the state of drug supply to the population in the Russian Federation (2008)]. N»YuDIAMED, 2009. 80 p.
12. Crawford C., Avula B., Lindsey A.T. et al. Analysis of Select Dietary Supplement Products Marketed to Support or Boost the Immune System. JAMA Network Open, 2022, vol. 5 (8), art. e2226040.
13. Maksimov M.L., Simakova S.A. Review of cases of acute liver failure due to dietary supplements. Bezopasnost’ i risk farmakoterapii, 2018, vol. 6, no. 2, pp. 68–77 (in Russ.).
14. Davydov S.A. Posteriori: dietary supplements and others. Remedium. Zhurnal o rossiyskom rynke lekarstv i meditsinskoy tekhnike, 2013, no. 10, pp. 50–55 (in Russ.).
15. Ivashkin V.T., Baranovskiy A.Yu., Raykhel’son K.L. et al. Drug-induced liver damage (clinical recommendations for doctors). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2019, vol. 29, no. 1, pp. 85–115 (in Russ.).
16. Bueverov A.O. Drug-induced liver damage: a problem that is still relevant. Doktor.Ru, 2016, no. 2 (119), pp. 57–64 (in Russ.).
17. Suk K.T., Kim D.J., Kim C.H., Park S.H., Yoon J.H. et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol, 2012, vol. 107, rr. 1380–1387.
18. Wai C.T., Tan B.H., Chan C.L. et al. Drug-induced liver injury at an Asian center: A prospective study. Liver Int, 2007, vol. 27, pp. 465–474.
19. Zhou Y., Yang L., Liao Z., He X., Guo H. Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21,789 patients. Eur. J. Gastroenterol. Hepatol, 2013, vol. 25, pp. 825–829.
20. Navarro V.J., Seeff L.B. Liver injury induced by herbal complementary and alternative medicine. Clin Liver Dis, 2013, vol. 17 (4), p. 715-x.
21. Chalasani N.P., Hayashi P.H., Bonkovsky H.L. et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, vol. 109 (7), rr. 950–966.
22. Reuben A., Koch D.G., Lee W.M. Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology, 2010, vol. 52 (6), pp. 2065–2076.
23. Chalasani N., Bonkovsky H.L., Fontana R. et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology, 2015, vol. 148 (7), rr. 1340–1352.e7.
24. Hunt C.M., Yuen N.A., Stirnadel-Farrant H.A., Suzuki A. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul. Toxicol. Pharmacol, 2014, vol. 70 (2), pp. 519–526.
25. Suh JI. Drug-induced liver injury. Yeungnam Univ J Med, 2020, vol. 37 (1), rr. 2–12.
26. Polunina T.E. Drug-induced liver damage. Meditsinskoe obozrenie, 2018, no. 7 (I), pp. 7–12 (in Russ.).
27. Lazebnik L.B., Golovanova E.V., Khlynova O.V. et al. Drug-induced liver damage (DILI) in adults. Eksperimental’naya i klinicheskaya gastroenterologiya, 2020, vol. 174 (2), pp. 29–54 (in Russ.).
28. Danan G., Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci, 2016, vol. 17 (1), r. 14.
29. Burt A.D., Portmann B.C., Ferrell L.D. MacSween’s Pathology of the Liver, Sixth Ed. 2012. Pp. 645–760.
30. Aithal G.P., Watkins P.B., Andrade R.J. et al. Review. Case definition andphenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 2011, vol. 89 (6), rr. 806–815.
31. Zhu S.S., Dong Y., Gan Y. et al. Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2010, vol. 24 (2), rr. 136–138.